I appreciate the post. I certainly understand the realities of investing in pre-revenue biotech companies. I also understand all of the relevant findings, the deferment of executive pay, the fact that nobody hits timelines, and the potential payoff if this thing were to hit.
I actually like biotech in the OTC world, as opposed to other sectors, for one big reason: there's plenty of verifiable data once you're in clinical stages that you can reasonably assess when making an investment decision, and there's a lot of structure to the path that a company must follow in order to make money. It's easier to put the pieces together in biotech than in other spaces, in my mind. However, this isn't clinical stage obviously, and they've been VERY tight with information on pre-clinical trials. This is the part of the game that I'm new to. So again, the question is: for others who have invested in pre-clinical biotechs, is it standard practice for a company to provide no updates whatsoever on the actual progress of or protocol for pre-clinical trials? Or is ENDV being abnormally tight-lipped on these matters?
That's the only thing that worries me. I have no data to look at, and they've given zero information on the pre-clinical trials they're working on.
News 
Market Data 
Discover 
